18F-氟脱氧葡萄糖摄取定量检测局部晚期头颈鳞癌放化疗后残留淋巴结病变:ECLYPS研究结果
ECLYPS前瞻性多中心研究在局部晚期头颈鳞癌患者放化疗后12周行标准化FDG-PET/CT,探索SUV体重阈值和病灶-本底比值识别淋巴结复发的价值,并以组织学、12个月FDG-PET/CT阴性或≥2年阴性随访为参考标准。中位随访20.4个月,124例可定量患者中观察23例(18.5%)颈部淋巴结复发。SUV70阈值2.2和SUV50/SUVliver阈值0.96的AUROC均为0.89,与Hopkins标准(AUROC=0.81)相比改善处于临界显著性(分别为p=0.040和p=0.094);独立验证队列中两者AUROC分别为0.93和0.95,与Hopkins评分(AUROC=0.91)相当且无统计学显著差异。
要点
- ECLYPS研究中124例可定量患者中位随访20.4个月,观察到23例(18.5%)颈部淋巴结复发。
- SUV70阈值2.2识别治疗后1年内淋巴结复发的AUROC=0.89,敏感度79.7%,特异度80.8%。
- SUV50/SUVliver阈值0.96的AUROC=0.89,敏感度79.7%,特异度82.8%,与SUV70相当。
核心结论
- FDG定量可检测局部晚期头颈鳞癌患者的淋巴结复发。
- 使用EARL标准化PET采集和重建时,绝对SUV指标(SUV70阈值2.2)表现稳健,而比值(SUV50/SUVliver阈值0.96)在常规临床工作中可能更有用。
- 在此条件下,定量诊断价值与Hopkins标准相当。
研究设计与样本
- ECLYPS为前瞻性多中心研究,对新诊断局部晚期头颈鳞癌患者在放化疗后12周行标准化FDG-PET/CT。
- 参考标准为组织学、治疗后12个月FDG-PET/CT阴性或≥2年阴性随访。
- 在ECLYPS中124例患者可进行定量分析,并在独立头颈鳞癌患者队列(n=127)中验证所得阈值。
主要发现
- ECLYPS中位随访20.4个月,124例可定量患者中观察到23例(18.5%)颈部淋巴结复发。
- SUV70阈值2.2的AUROC=0.89,敏感度79.7%,特异度80.8%,为识别治疗后1年内淋巴结复发的最佳指标。
- SUV50/SUVliver阈值0.96的AUROC=0.89,敏感度79.7%,特异度82.8%,在病灶-本底比值中表现最佳。
- 与Hopkins标准(AUROC=0.81)相比,SUV70和SUV50/SUVliver的改善分别为临界显著(p=0.040)和临界显著(p=0.094)。
- 验证队列中SUV70的AUROC=0.93、SUV50/SUVliver的AUROC=0.95,与Hopkins评分(AUROC=0.91)相当且无统计学显著差异。
关键数值与推荐
- SUV70阈值2.2:AUROC=0.89,敏感度79.7%,特异度80.8%。
- SUV50/SUVliver阈值0.96:AUROC=0.89,敏感度79.7%,特异度82.8%。
- Hopkins标准:AUROC=0.81。
- 验证队列:SUV70的AUROC=0.93,SUV50/SUVliver的AUROC=0.95,Hopkins评分AUROC=0.91,无统计学显著差异。
临床怎么用
- 使用EARL标准化PET采集和重建时,绝对SUV指标(SUV70阈值2.2)表现稳健。
- 比值(SUV50/SUVliver阈值0.96)在常规临床工作中可能更有用。
- 在此条件下,定量的诊断价值与Hopkins标准相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Hopkins criteria were introduced for nodal response evaluation after therapy in head and neck cancer, but its superiority over quantification is not yet confirmed. METHODS: SUVbody weight thresholds and lesion-to-background ratios were explored in a prospective multicenter study of standardized FDG-PET/CT 12 weeks after CRT in newly diagnosed locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients (ECLYPS). Reference standard was histology, negative FDG-PET/CT at 12 months after treatment or ≥ 2 years of negative follow-up. Area under the receiver operator characteristics curves (AUROC) were estimated and obtained thresholds were validated in an independent cohort of HNSCC patients (n = 127). RESULTS: In ECLYPS, 124 patients were available for quantification. With a median follow-up of 20.4 months, 23 (18.5%) nodal neck recurrences were observed. A SUV70 threshold of 2.2 (AUROC = 0.89; sensitivity = 79.7%; specificity = 80.8%) was identified as optimal metric to identify nodal recurrence within 1 year after therapy. For lesion-to-background ratios, an SUV50/SUVliver threshold of 0.96 (AUROC = 0.89; sensitivity = 79.7%; specificity = 82.8%) had the best performance. Compared with Hopkins criteria (AUROC = 0.81), SUV70 and SUV50/SUVliver provided a borderline significant (p = 0.040 and p = 0.094, respectively) improvement. Validation of thresholds yielded similar AUROC values (SUV70 = 0.93, SUV50/SUVliver = 0.95), and were comparable to the Hopkins score (AUROC = 0.91; not statistically significant). CONCLUSION: FDG quantification detects nodal relapse in LAHNSCC patients. When using EARL standardized PET acquisitions and reconstruction, absolute SUV metrics (SUV70 threshold 2.2) prove robust, yet ratios (SUV50/SUVliver, threshold 0.96) may be more useful in routine clinical care. In this setting, the diagnostic value of quantification is comparable to the Hopkins criteria. TRIAL REGISTRATION: US National Library for Medicine, NCT01179360. Registered 11 August 2010, https://clinicaltrials.gov/ct2/show/NCT01179360.
引用
- Helsen N, Van den Wyngaert T, Carp L, et al. Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study. Eur J Nucl Med Mol Imaging. 2020. PMID: 32040611. doi:10.1007/s00259-020-04710-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。